Aiuti, Alessandro http://orcid.org/0000-0002-5398-1717
Pasinelli, Francesca
Naldini, Luigi http://orcid.org/0000-0002-7835-527X
Article History
First Online: 15 August 2022
Competing interests
: A.A. is PI of clinical trials sponsored by Orchard Therapeutics, which licensed gene therapy products for ADA-SCID, WAS, metachromatic leukodystrophy (MLD), β-thalassemia and mucopolysaccharidosis type I (MPS-I) originally developed at SR-Tiget. A.A. is a member of the Committee for Advanced Therapies (CAT) and his views are personal and may not be understood or quoted as being made on behalf of the European Medicines Agency (EMA). L.N. is an inventor on pending and issued patents on LV technology and gene editing filed by the Salk Institute, Cell Genesys, Telethon Foundation and/or San Raffaele Scientific Institute. L.N. is a founder of, owns equity in, and is a consultant and member of the scientific advisory board of Genenta Science, a biotechnology company aiming at developing cancer gene therapy by tumor-infiltrating monocytes, and Genespire, a biotechnology startup developing lentiviral-vector-based liver gene transfer and hematopoietic cell gene editing. F.P. has no competing interests.